InsidersTradesSigma
Follow the BeOne Medicines Ltd. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, BeOne Medicines Ltd. has logged 312 reports. Market capitalisation: €42.6bn. The latest transaction was reported on 27 August 2026 (Cession). Among the most active insiders: OYLER JOHN. All data is openly available.
BeOne Medicines Ltd., listed on XNAS in the Healthcare & Pharma sector, reported a total of 234 insider trading declarations in the last 90 days. The total amount sold by insiders reached approximately 353.69 million euros, while there were no purchases recorded. The Chief Executive Officer, John Oyler, was involved in the majority of the transactions, with a total sale amount of approximately 310.46 million euros across 109 declarations. Other notable insiders include John V Oyler, who sold approximately 39.68 million euros in one declaration, and Oyler John Victor, with sales totaling about 34.73 million euros over 34 declarations. Recent notable sales include a proposed sale by John V Oyler on July 10, 2026, and multiple sales by John Oyler throughout July 2026, with amounts ranging from approximately 11.24 million euros to 13.98 million euros.
Auto-generated summary, refreshed daily.Updated 2d ago
312
Insider Decl.
n/a
Thresholds
n/a
10 ops.
Buy Volume
€306m
182 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BeOne Medicines Ltd. Strong Buy (bullish), based on 28 analysts. Average price target: US$432.16.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 12,016 of 28,932 companies
56.2
score / 100
Value43
Quality69
FCF yld2.0%
Earn yld0.7%
EV/EBITDA·
ROE15%
Gross mgn87%
Net mgn5.4%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations312 total
280 shares@ US$380.00American Depositary SharesSEC:0001739452-26-000011:0
2,075 shares@ US$380.000.0019% mcap75.7% of flowADSSEC144:0001950047-26-008641
812 shares@ US$194.470.0004% mcap3.1% of flowAmerican Depositary SharesSEC:0001980648-26-000024:0
1,058 shares@ US$213.320.0006% mcap4.4% of flowAmerican Depositary SharesSEC:0001980648-26-000024:1
796 shares@ US$159.030.0003% mcap2.4% of flowAmerican Depositary SharesSEC:0001980648-26-000024:2
2,666 shares@ US$360.000.0024% mcap18.6% of flowAmerican Depositary SharesSEC:0001980648-26-000024:3
713,596 shares@ HK$27.550.0062% mcap6.2% of flowShareXHKGHKEX:DA20260813E00285
1,495,143 shares@ HK$27.52880.013% mcap13.1% of flowShareXHKGHKEX:DA20260813E00286
921,791 shares@ HK$27.83870.0080% mcap8.2% of flowShareXHKGHKEX:DA20260813E00284
2,978,495 sharesShareXHKGHKEX:DA20260813E00283
67 shares@ US$350.000.0001% mcap0.0% of flowAmerican Depositary SharesSEC:0001042047-26-000019:0
3,673 shares@ US$353.31910.0033% mcap0.4% of flowAmerican Depositary SharesSEC:0001042047-26-000019:2
3,476 shares@ US$355.65630.0031% mcap0.3% of flowAmerican Depositary SharesSEC:0001042047-26-000019:4
12,418 shares@ US$356.6180.011% mcap1.2% of flowAmerican Depositary SharesSEC:0001042047-26-000019:5
15,869 shares@ US$357.66990.014% mcap1.6% of flowAmerican Depositary SharesSEC:0001042047-26-000019:6
45,044 shares@ US$358.69540.041% mcap4.4% of flowAmerican Depositary SharesSEC:0001042047-26-000019:7
21,254 shares@ US$359.50060.019% mcap2.1% of flowAmerican Depositary SharesSEC:0001042047-26-000019:8
3,680 shares@ US$360.63320.0034% mcap0.4% of flowAmerican Depositary SharesSEC:0001042047-26-000019:9
13,695 shares@ US$359.31680.012% mcap1.4% of flowAmerican Depositary SharesSEC:0001042047-26-000019:10
8,081 shares@ US$360.33280.0074% mcap0.8% of flowAmerican Depositary SharesSEC:0001042047-26-000019:11
14,569 shares@ US$361.47080.013% mcap1.4% of flowAmerican Depositary SharesSEC:0001042047-26-000019:12
11,568 shares@ US$362.33990.011% mcap1.2% of flowAmerican Depositary SharesSEC:0001042047-26-000019:13
13,403 shares@ US$363.45180.012% mcap1.3% of flowAmerican Depositary SharesSEC:0001042047-26-000019:14
3,176 shares@ US$365.26420.0029% mcap0.3% of flowAmerican Depositary SharesSEC:0001042047-26-000019:16
1,200 shares@ US$366.3120.0011% mcap0.1% of flowAmerican Depositary SharesSEC:0001042047-26-000019:17
25 of 312 declarations
About BeOne Medicines Ltd.
BeOne Medicines Ltd. is a global biopharmaceutical company listed on the NASDAQ (United States) under the ticker ONC, with additional listings in Hong Kong and Shanghai. The company, formerly known as BeiGene, completed a name change and redomiciliation on May 27, 2025, moving its place of incorporation from the Cayman Islands to Switzerland while keeping its Nasdaq Global Select Market listing intact. For international investors, this means BeOne is a U.S.-listed oncology company with a Swiss legal domicile and a globally distributed operating footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000110465925053039/tm2515777d11_posasr.htm)) Founded in 2010 by John V. Oyler and Xiaodong Wang, BeOne was built around a clear mission: to develop innovative cancer therapies and make them more accessible across global markets. The company’s operational footprint spans major hubs including San Carlos, California; Cambridge, Massachusetts; and Basel, Switzerland, alongside manufacturing and R&D capabilities in the United States, China, Europe, and Latin America. BeOne also highlights a broad global research network, with clinical development and commercial activities across multiple continents. ([beonemedicines.com](https://beonemedicines.com/about/history/?utm_source=openai)) BeOne is primarily an oncology-focused business. Its commercial foundation rests on two key medicines: BRUKINSA (zanubrutinib), a BTK inhibitor used in several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy used in solid tumors and hematologic indications. Beyond these marketed products, the company is advancing a broad pipeline that spans blood cancers, lung cancer, breast/gynecological cancers, gastrointestinal cancers, and certain rare cancers. BeOne states that it has more than 30 investigational medicines in development, underscoring a pipeline-driven growth model rather than a narrow single-asset profile. ([beonemedicines.com](https://beonemedicines.com/science/medicines/?utm_source=openai)) From a competitive perspective, BeOne operates in a highly crowded oncology landscape against major global pharma groups and specialist biotech peers. Its differentiation lies in an integrated development model, a wide geographic commercialization strategy, and a stated focus on improving patient access. The company reports regulatory approvals for its internally developed medicines in more than 75 countries, which gives it meaningful international reach and supports the view that it is building a global oncology platform rather than a purely regional business. ([beonemedicines.com](https://beonemedicines.com/about/our-company/faqs/?utm_source=openai)) Recent developments have been constructive. In February 2026, BeOne reported full-year 2025 revenue of $5.3 billion and highlighted strong global momentum for BRUKINSA. In May 2026, the company announced U.S. FDA approval of BEQALZI (sonrotoclax), and it also received FDA Priority Review for TEVIMBRA in a HER2-positive first-line indication. These updates reinforce the company’s clinical execution and regulatory momentum, both of which are central to the investment case in oncology biotech. ([ir.beonemedicines.com](https://ir.beonemedicines.com/news/beone-medicines-announces-fourth-quarter-and-full-year-2025-financial-results-highlighting-global-success-of/6559b41c-7beb-45ca-bc76-5e1c9cdb26cc?utm_source=openai))
